{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:56:04Z","timestamp":1771264564089,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.seminhematol.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T07:31:29Z","timestamp":1502523089000},"page":"182-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9478","authenticated-orcid":false,"given":"Giacomo","family":"Zoppellaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-0325","authenticated-orcid":false,"given":"Serena","family":"Granziera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-4621","authenticated-orcid":false,"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2017.08.002_bib1","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of thrombosis in multiple myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00277-008-0561-1","article-title":"Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone","volume":"88","author":"Klein","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.thromres.2008.09.008","article-title":"Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy","volume":"123","author":"Musallam","year":"2009","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib8","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib9","unstructured":"Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/wwwohrica\/programs\/clinical\\_epidemiology\/oxfordasp. 2012."},{"key":"10.1053\/j.seminhematol.2017.08.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib13","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428190701647887","article-title":"Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma","volume":"48","author":"Niesvizky","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib14","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1078155215569555","article-title":"Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy","volume":"22","author":"Dede","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.23504","article-title":"Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens","volume":"88","author":"Bagratuni","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/annonc\/mdm178","article-title":"VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group","volume":"18","author":"Zervas","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ajco.12013","article-title":"Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital","volume":"9","author":"Alexander","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib23","doi-asserted-by":"crossref","unstructured":"Kahn S.R., Lim W., Dunn A.S., et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195S\u2013226.","DOI":"10.1378\/chest.141.6.1645"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib24","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","article-title":"Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416","volume":"21","author":"Kuenen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib26","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Rajkumar","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide\u2014a systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib28","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2.2016: clinical practice guidelines in oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2017.08.002_bib29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196317300495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196317300495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:25:13Z","timestamp":1758522313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196317300495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0037196317300495"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2017.08.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}